#China #Shanghai #CFO #Harbour BioMed #Youchen Chen

Harbour BioMed's New Chapter: Youchen Chen as CFO

On April 9, 2025, Harbour BioMed, a prominent biopharmaceutical company with a focus on novel antibody therapeutics, announced the appointment of Youchen (YC) Chen as its new Chief Financial Officer (CFO). With his extensive background in finance and a strong strategic vision, YC Chen is expected to play a crucial role in the company's growth and operations.

Based in both Shanghai and Hong Kong SAR, YC will report directly to Dr. Jingsong Wang, the Founder and CEO of Harbour BioMed. Since joining the organization in 2023, Chen has significantly expanded his portfolio of responsibilities, contributing to development efforts across Investor Relations, Corporate Development, and Finance. His collaborative leadership style has been instrumental in forming key strategic partnerships while overseeing vital transactions and the company's global financial landscape.

Dr. Wang expressed his confidence in Chen's capabilities, highlighting his strategic approach and financial acumen that have positively influenced the company’s initiatives and overall value creation. As Chen embarks on his new role, he emphasizes his commitment to advancing Harbour BioMed's strategic objectives and delivering substantial value to stakeholders as part of their mission to develop impactful therapies.

Before his tenure at Harbour BioMed, Chen served as CFO at a clinical-stage radiopharmaceutical startup where he demonstrated adept financial governance and operational insights. His experience within the finance community includes a notable position as Vice President at Credit Suisse China, where he advised healthcare and tech companies on strategic investment and financing avenues. Additionally, he has held roles focused on Corporate Finance at Yidu Tech and gained invaluable audit experience at KPMG.

Yu Chen holds a bachelor's degree in law from Fudan University and has pursued an MBA at Georgetown University's McDonough School of Business, further demonstrating his commitment to continuous education by currently seeking an advanced degree at Harvard Medical School.

The Vision Moving Forward

Chen’s appointment comes at a pivotal time for Harbour BioMed, which is dedicated to establishing a strong pipeline of novel antibody therapeutics within immunology and oncology. The company employs a proprietary antibody technology platform, known as Harbour Mice®, allowing the generation of fully human monoclonal antibodies. This platform facilitates significant advancements in developing next-generation therapeutic antibodies through innovative methodologies like HCAb-based bispecific immune cell engagers (HBICE®), enabling enhanced tumor-fighting capabilities beyond traditional treatments.

The future appears bright for Harbour BioMed as it optimizes operations and expands its reach under the guidance of Youchen Chen. Combining his financial leadership with the company's pioneering therapeutic approaches sets a compelling stage for growth, innovation, and an enduring commitment to transformative healthcare solutions. As Chen transitions into his role, stakeholders eagerly anticipate the advancements that Harbour BioMed will make in its quest to innovate groundbreaking therapies while improving shareholder returns and enhancing patient lives.

In conclusion, the path forward under Youchen Chen's financial stewardship promises enhanced strategic direction, effective capital management, and an unwavering focus on innovation, positioning Harbour BioMed for much success ahead.